Antibody-based treatment of acute myeloid leukaemia

Bibliography

• CASSILETH PA, HARRINGTON DP, APPELBAUM FR et al.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl. J. Med. (1998) 339:1649–1656.
   PubMed Web of Science ®Google Scholar
• STOCKERL-GOLDSTEIN KE,BLUME KG: Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Hematopoietic Cell Transplantation. Thomas ED, Blume KG,Forman SJ (Eds), Blackwell Science, Inc., Oxford (1999):823–834.
   Google Scholar
• SABBATH KD, BALL ED, LARCOM P, DAVIS DB, GRIFFIN JD. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J. Clin. Invest. (1985) 75:746–756.
   PubMed Web of Science ®Google Scholar
• ANDREWS RG, TAKAHASHI M, SE GAL GM et al.: The L4F3 antigen is expressed by unipotent colony-forming cells but not by their precursors. Blood (1986) 68:1030–1035.
   Google Scholar
• OMARY MB, TROWBRIDGE IS, BATTIFORA HA: Human homologue of murine T-200 glycoprotein. I Exp. Med. (1980) 152:842–852.
   PubMed Web of Science ®Google Scholar
• WAHREN B, GADLER F, GAHRTON Get al: NCA: a differentiation antigen ofmyelopoietic cells in human and hominoid monkeys. Ann. NY Acad. Sci. (1983) 417:344–358.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Ritwdmab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Clin. Oncol (1998) 16:2825–2833.
   Google Scholar
• KEATING MJ, FLINN I, JAIN V et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood(2002) 99:3554–3561.
   PubMed Web of Science ®Google Scholar
• WEISBURG J, ROEPE PD, DZEKUNOV S, SCHEINBERG DA.Intracellular pH and multidrug resistanceregulate complement-mediated cytotoxicity of nucleated human cells." Biol. Chem.(1999) 274:10877–10888.
   Google Scholar
• SCHEINBERG DA, LOVETT D, DIVGI CR et al: A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. j Clin. Omni (1991) 9:478–490.
   PubMed Web of Science ®Google Scholar
• CARON PC, CO MS, BULL MK et al: Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. (1992) 52:6761–6767.
   PubMed Web of Science ®Google Scholar
• CARON PC, JURCIC JG, SCOTT AM et al.: A Phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood (1994) 83: 1760-1768.
   Google Scholar
• XU Y, SCHEINBERG DA: Elimination ofhuman leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clin. Cancer Res. (1995) 1:1179–1187.
   PubMed Web of Science ®Google Scholar
• CARON PC, DUMONT L, SCHEINBERG DA: Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin. Cancer Res. (1998) 4:1421–1428.
   PubMed Web of Science ®Google Scholar
• FELDMAN E, KALAYCIO M,WEINER G et al.: Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia (2003) 17:314–318.
   Google Scholar
• JURCIC JG, NIMER SD,SCHEINBERG DA et al.: Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood (2001) 98:2651–2656.
   Google Scholar
• JURCIC JG, DEBLASIO T, DUMONT L,YAO TJ, SCHEINBERG DA: Molecular remission induction with retinoic acid and anti- CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin. Cancer Res. (2000) 6:372–380.
   PubMed Web of Science ®Google Scholar
• •Unconjugated antibody therapy can eliminate minimal residual disease detectable by RT-PCR.
   Google Scholar
• JURCIC JG: Antibody therapy for residualdisease in acute myelogenous leukemia. Grit. Rev. Oncol (2001) 38:37–45.
   PubMed Web of Science ®Google Scholar
• FELDMAN E, STONE RM, BRANDWEIN J et al: Phase III randomized trial of an anti-CD33 monoclonal antibody (HuM195) in combination with chemotherapy compared to chemotherapy alone in adults with refractory or first-relapse acute myeloid leukemia (AML). Proc. Am. Soc. Clin. Omni (2002) 21:261a.
   Google Scholar
• CARON PC, LAI L, SCHEINBERG DA: Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (HuM195) (anti-CD33) in myelogenous leukemia. Gin. Cancer Res. (1995) 1:63–70.
   Web of Science ®Google Scholar
• SOIFFER RJ, MURRAY C,COCHRAN K et al.: Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood (1992) 79:517–526.
   Google Scholar
• CALIGIURI MA, MURRAY C, SOIFFER RJ et al.: Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.' Gin. Oncol (1991) 9:2110–2119.
   Google Scholar
• KOSSMAN SE, SCHEINBERG DA, JURCIC JG, JIMENEZ J, CARON PC: A Phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Gin. Cancer Res. (1999) 5:2748–2755.
   Web of Science ®Google Scholar
• HUMM JL: A microdosimetric model of astatine-211 labeled antibodies forradioimmunotherapy. hat.OncolBiol. Phys. (1987) 13:1767–1773.
   PubMedGoogle Scholar
• SCHWARTZ MA, LOVETT DR, REDNER A et al.: Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.Clin. Omni (1993) 11:294–303.
   Google Scholar
• BURKE JM, CARON PC, PAPADOPOULOS EB et al: Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advance myeloid leukemias. Bone Marrow Transplant. (2003) 32:549–556.
   PubMed Web of Science ®Google Scholar
• NIKULA TK, BOCCHIA M, CURCIO MJ et al.: Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgGimmunoreactivity. MM. Immunol (1995) 32:865–872.
   PubMed Web of Science ®Google Scholar
• SCHEINBERG DA, STRAND M: Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res. (1983) 43:265–272.
   PubMed Web of Science ®Google Scholar
• CARRASQUILLO JA, WHITE JD, PAIK CH et al.: Similarities and differencesinand 90Y-labeled 1B4M-DTPA anti-Tac monoclonal antibody distribution. J. Nucl. Med. (1999) 40:268–276.
   PubMed Web of Science ®Google Scholar
• LOVQVIST A, HUMM JL, SHEIKH A et al.: PET imaging of 86Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between 86Y and 111In radiolabels. Nucl. Med. (2001) 42:1281–1287.
   Web of Science ®Google Scholar
• JURCIC JG, DIVGI CR,MCDEVITT MR et al.: Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. Proc. Am. Soc. Clin. Omni (2000) 19:8a.
   Google Scholar
• •The use of radiometals can overcome limitations seen with radioirnmunotherapyusing 131
   Google Scholar
• APPELBAUM FR, MATTHEWS DC, EARY JF et al.: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation (1992) 54:829–833.
   PubMed Web of Science ®Google Scholar
• RUFFNER KL, MATTHEWS DC: Current uses of monoclonal antibodies in the treatment of acute leukemia. Semin. Omni (2000) 27:531–539.
   Google Scholar
• MATTHEWS DC, APPELBAUM FR, EARY JF et al.: Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood (1995) 85:1122–1131.
   PubMed Web of Science ®Google Scholar
• MATTHEWS DC, APPELBAUM FR, EARY JF et al: Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood (1999) 94:1237–1247.
   PubMed Web of Science ®Google Scholar
• •1311-labeled anti-CD45 antibody can deliver substantial supplemental doses of radiation to the marrow prior to BMT
   Google Scholar
• MATTHEWS DC, APPELBAUM FR, EARY JF et al: I-131-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission. Blood (1996) 88:142a.
   Google Scholar
• BUNJES D, BUCHMANN I,DUNCKER C et al.: Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a Phase I-II study. Blood (2001) 98:565–572.
   Google Scholar
• HARTMANN F, HORAK EM, GARMESTANI K et al.: Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res. (1994) 54:4362–4370.
   PubMed Web of Science ®Google Scholar
• BALLANGRUD AM, YANG WH, CHARLTON DE et al.: Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. (2001) 61:2008–2014.
   PubMed Web of Science ®Google Scholar
• SANDMAIER BM, BETHGE WA, WILBUR DS et al: Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood (2002) 100:318–326.
   PubMed Web of Science ®Google Scholar
• BETHGE WA, WILBUR DS, STORB R et al.: Selective T-cell ablation with bismuth-213 labeled anti-TCRal3 as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood(2003) 101:5068–5075.
   PubMed Web of Science ®Google Scholar
• AXWORTHY DB, RENO JM, HYLARIDES MD et al.: Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA (2000) 97:1802–1807.
   PubMed Web of Science ®Google Scholar
• ZHANG M, YAO A, GARMESTANI K et al.: Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth-213. Blood(2002) 100:208–216.
   PubMed Web of Science ®Google Scholar
• ZHANG M, ZHANG Z, GARMESTANI K et al.: Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl. Acad. Sci. USA (2003) 100:1891–1895.
   PubMed Web of Science ®Google Scholar
• MCDEVITT MR, FINN RD, MA D, LARSON SM, SCHEINBERG DA: Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. .1 Nucl. Med. (1999) 40:1722–1727.
   PubMed Web of Science ®Google Scholar
• NIKULA TK, MCDEVITT MR, FINN RD et al.: Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. Nucl. Med. (1999) 40:166–176.
   Web of Science ®Google Scholar
• JURCIC JG, LARSON SM, SGOUROS G et al.: Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 100:1233–1239.
   PubMed Web of Science ®Google Scholar
• ••This is the first study to demonstrate thefeasibility and antiturnour effects of a-particle immunotherapy in humans.
   Google Scholar
• BURKE JM, JURCIC JG, DIVGI DR et al.: Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-labeled anti-CD33 monoclonal antibody HuM195 in acute myeloid leukemia (AML). Blood (2002) 100:339a.
   Web of Science ®Google Scholar
• MCDEVITT MR, MAD, LAI LT et al: Tumor therapy with targeted atomic nanogenerators. Science (2001) 294:1537–1540.
   PubMed Web of Science ®Google Scholar
• •Use of an in vivo a-particle generator enhances the potency of radioimmunoconjugates.
   Google Scholar
• ZEIN N, SINHA AM, MCGAHREN WJ, ELLESTAD GA: Calicheamicin gamma 11: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science (1988) 240:1198–1201.
   PubMed Web of Science ®Google Scholar
• SIEVERS EL, APPELBAUM FR, SPIELBERGER RT et al: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 93:3678–3684.
   PubMed Web of Science ®Google Scholar
• SIEVERS EL, LARSON RA,STAUDTMAUER EA et al: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.' Clin. Oncol. (2001) 19:3244–3254.
   Web of Science ®Google Scholar
• •Antibody-targeted chemotherapy can produce clinical responses with acceptable toxicity in patients with relapsed AML.
   Google Scholar
• LARSON RA, BOOGAERTS M, ESTEY E et al: Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia (2002) 16:1627–1636.
   PubMed Web of Science ®Google Scholar
• BROSS PF, BEITZ J, CHEN G et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloidleukemia. Clin. Cancer Res. (2001) 7:1490–1496.
   PubMed Web of Science ®Google Scholar
• SIEVERS E, LARSON R, ESTEY E et al.:Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation. Blood (2002) 100:89a.
   PubMed Web of Science ®Google Scholar
• WADLEIGH M, RICHARDSON PG, ZAHRIEH D et al.: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood (2003) 102:1578–1582.
   PubMed Web of Science ®Google Scholar
• RAJVANSHI P, SCHULMAN H, SIEVERS E et al: Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood (2002) 99:10–14.
   PubMedGoogle Scholar
• GILES FJ, KANTARJIAN HM, KORNBLAU SM et al.: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer (2001) 92:406–413.
   PubMed Web of Science ®Google Scholar
• KELL WJ, BURNETT AK, CHOPRA R et al.: Simultaneous administration of Mylotarg (gemtuzumab ozogamicin) with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia: a feasibility study. Blood (2003) (In Press).
   Google Scholar
• •Addition of GO to conventional chemotherapy is feasible and produces high remission rates.
   Google Scholar
• DEANGELO DJ, SCHIFFER C, STONE R et al.: Interim analysis of a Phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients 60 years old with untreated acute myeloid leukemia. Blood (2002) 100:198a–199a.
   Google Scholar
• DEANGELO DJ, LIU D, STONE R et aL: Preliminary report of a Phase II study of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin in patients 60 years of age with de novo acute myeloid leukemia. Proc. Am. Soc.Clin. Oncol (2002) 22:578.
   Google Scholar
• BONNET D, DICK JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. (1997) 3:730–737.
   PubMed Web of Science ®Google Scholar
• ESTEY E, GILES FJ, BERAN M et al.: Experience with gemtuzumab ozogamicin ('Mylotarg') and all- trans retinoic acid in untreated acute promyelocytic leukemia. Blood (2002) 99:4222–4224.
   PubMed Web of Science ®Google Scholar
• APOSTOLIDOU E, CORTES J, TSIMBERIDOU A et al.: Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leak. Res. (2003) 27:887–891.
   PubMed Web of Science ®Google Scholar
• MCGRAW KJ, ROSENBLUM MG, CHEUNG L, SCHEINBERG DA: Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol Immunother. (1994) 39:364–374.
   Google Scholar
• XU Y, XU Q, ROSENBLUM MG, SCHEINBERG DA: Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice. Leukemia (1996) 10:321–326.
   PubMed Web of Science ®Google Scholar
• DUZKALE H, PAGLIARO LC, ROSENBLUM MG et al: Bone marrowpurging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotwdn HuM195/rGel. Biol. Blood Marrow Transplant. (2003) 9:364-372.Affiliation
   Google Scholar